Five Prime Therapeutics, Inc. (FPRX) News
Filter FPRX News Items
FPRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FPRX News Highlights
- For FPRX, its 30 day story count is now at 4.
- Over the past 21 days, the trend for FPRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about FPRX are AMGN.
Latest FPRX News From Around the Web
Below are the latest news stories about Five Prime Therapeutics Inc that investors may wish to consider to help them evaluate FPRX as an investment opportunity.
Amgen Completes The Acquisition Of Five Prime TherapeuticsAmgen has completed the acquisition of the clinical-stage biotechnology company Five Prime Therapeutics. Amgen had previously announced a tender offer to buy all outstanding common stock at the price of $38.00 per share in cash. The aggregate payment that was to be made for the merger is $1.9B, excluding transaction expenses. Amgen is a biotech company that focuses on unlocking biological potential and innovations that cater to patients suffering from serious illnesses. Amgen (AMGN) focuses on unmet needs in the human therapeutics field, and Five Prime Therapeutics (FPRX) will add to its overall oncology portfolio. |
Amgen Successfully Completes Acquisition Of Five Prime TherapeuticsAmgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses. |
SHAREHOLDER ALERT: WeissLaw LLP Reminds HWCC, FI, SVBI, and FRPX Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
Halper Sadeh LLP Investigates the Following Mergers - TPCO, STAY, KSU, CUB, AEGN, FPRX; Shareholders Are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: |
Lifshitz Law Firm, P.C. Announces Investigation of FPRX, NBLX, PAND, and SHBINEW YORK, NY / ACCESSWIRE / March 21, 2021 / Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Lifshitz Law Firm, P. |
BREAKING NEWS ALERT: Halper Sadeh LLP Investigates CTB, FFG, PAND, SVBI, FPRX; Shareholders are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
Outbidding 14 others and then themselves: How Amgen spent $2 billion on a biotech that had been on the brinkIn the summer of 2020, you could get a share of Five Prime Therapeutics for less than a latte, but the company's leadership knew that could soon change. Five Prime was nearing a readout on their Phase II trial for gastric cancer. If it proved successful, it could return them |
Though Potential Bidders Moved Away, Amgen's Bid For Five Prime Outlasted 15 SuitorsEarlier this month, biotech giant Amgen Inc (NASDAQ: AMGN ) announced a $1.9 billion buyout of Five Prime Therapeutics Inc (NASDAQ: FPRX ) that outlasted around 15 potential collaborators. Background: Amgen’s interest in FPRX goes back to 2019 when it, alongside others (not named in the SEC filing ), tried to bet on FPRX’s pipeline. In November, Five Prime’s bemarituzumab data hit the primary endpoint goal , a moment the company had been waiting for quite some time. The Phase 2 study enrolled 155 people with FGFR2b-positive tumors and randomized them to receive bemarituzumab or placebo on top of chemotherapy. Progression-free survival in patients in the bemarituzumab arm on top of chemotherapy was 9.5 months, more than two months longer than in the control arm. Bids To Collaborate: Afte... |
Benefitfocus and Five Prime Therapeutics See Analyst ActionIndaba Capital wants a board “refresh” at benefits-management software firm Benefitfocus. Magnetar Capital disclosed a large stake in biopharmaceutical firm Prime Therapeutics. |
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of FRTA, AEGN, FPRX, and MIK BuyoutsWILMINGTON, Del., March 18, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating: Forterra, Inc. (NASDAQ GS: FRTA) regarding possible breaches of fiduciary duties and other violations of law related to Forterra’s agreement to be acquired by Quikrete Holdings, Inc. Under the terms of the agreement, Forterra’s shareholders will receive $24.00 in cash per share. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-forterra-inc. Aegion Corporation (NASDAQ GS: AEGN) regarding possible breaches of fiduciary duties and other violations of law related to Aegion’s agreement to be acquired by affiliates of New Mountain Partners, VI, L.P. Under the terms of the agreement, Aegion’s shareholders will receive $26.00 in cash per share... |